There is no excuse for collecting this important information, but not revealing it to the public. The only legitimate justification for this would be if there were no reported conflicts of interest. In such a case, the report could have included a statement indicating that none of the report's authors reported a conflict of interest.

In fact, the bulk of the evidence suggests that the introduction of the cigarette filter, while obviously not making cigarettes substantially safer, did result in small but measurable declines in cancer risk. These declines occurred due to a tremendous reduction in tar yield, from levels as high as 40-50 mg down to less than 20 mg. The evidence suggests that further declines - to levels below this massive initial drop - were not associated with further declines in cancer risk.

BAT offshoot Nicoventures first sought a meeting with the Therapeutic Goods Administration (TGA) in November 2013 "to fully explain our medicines-based approach to these agencies".

I conclude as follows: "By promoting a message that flies in the face of the government's own statistics--which show a sharp decline in youth smoking concurrent with a dramatic increase in e-cigarette experimentation--some federal public health official appear to be trying to create a "gateway" narrative where none exists."

In fact, one of the complaints in the comment is that "E-cigarette companies are marketing e-cigarettes as healthier alternatives to cigarette smoking."

Dr. Henningfield: "Dr. Henningfield is a Principal at, and derives most of his income from, Pinney Associates, a firm that currently provides to GSK on an exclusive basis consulting services regarding smoking-cessation products. His formal title is: Vice President, Research & Health Policy. Through his association with Pinney Associates, Dr. Henningfield advises GSK specifically on the development of nicotine-replacement therapies and treatments for tobacco dependence. Pinney Associates has received on average more than $2 million per year in revenue from pharmaceutical companies, more than half of which relates to smoking-cessation products. In addition, during the last decade, Dr. Henningfield has received grant support for research and writing from GSK on at least eight occasions. Dr. Henningfield is also a partner in a company that holds patents for a nicotine replacement-therapy product. He has estimated that, if thess patents are successfully licensed, they could be worth more than $1 million to him as a partner in that company. Thus, Dr. Henningfield has a financial interest in bringing about regulatory policies that will drive current smokers to use nicotine-replacement-therapy products."

LAST：kangertech original ego thread evod cartomizer |NEXT：2014 best qualty factory price disposable electronic cigarette e disposable cigarette green smoking